mononegavirus
includ
number
highli
contagi
sever
diseasecaus
virus
anim
human
control
viral
diseas
develop
vaccin
either
classic
method
recombin
dna
viru
vector
attempt
year
recent
revers
genet
mononegavirus
develop
use
gener
infecti
virus
possess
genom
deriv
clone
cdna
order
studi
consequ
effect
viral
gene
manipul
phenotyp
technolog
allow
us
develop
novel
candid
vaccin
particular
varieti
differ
attenu
strategi
produc
rang
attenu
mononegaviru
vaccin
studi
addit
ideal
natur
live
vaccin
recombin
mononegavirus
express
foreign
protein
also
produc
aim
develop
multival
vaccin
one
pathogen
recombin
mononegavirus
current
evalu
new
viral
vector
vaccin
revers
genet
could
great
potenti
prepar
vaccin
mani
mononegavirus
world
organis
anim
health
oie
proclaim
may
countri
territori
rinderpestsuscept
anim
free
diseas
follow
food
agricultur
organ
fao
unit
nation
declar
june
diseas
erad
rinderpest
second
viru
diseas
smallpox
erad
human
effort
rinderpest
highli
contagi
viral
diseas
affect
sever
speci
wild
domest
clovenhoof
anim
notabl
cattl
buffalo
mani
speci
includ
sheep
goat
show
milder
clinic
sign
diseas
infect
see
front
matter
elsevi
bv
right
reserv
mortal
rate
could
reach
highli
suscept
cattl
buffalo
herd
fao
inform
indic
rinderpest
epizoot
associ
fall
roman
empir
conquest
christian
europ
charlemagn
french
revolut
impoverish
russia
extens
famin
africa
effort
fight
rinderpest
connect
found
world
first
veterinari
school
lyon
franc
furthermor
outbreak
rinderpest
import
anim
belgium
impetu
intern
cooper
control
anim
diseas
key
factor
lead
establish
oie
outbreak
kill
million
anim
alon
africa
southern
asia
middl
east
outbreak
pakistan
kill
ten
thousand
cattl
buffalo
yak
sinc
fao
spearhead
global
rinderpest
erad
programm
grep
oie
intern
atom
energi
agenc
iaea
institut
partner
govern
region
organ
interafrican
bureau
anim
resourc
commun
worldwid
last
confirm
outbreak
buffalo
found
infect
kenya
last
vaccin
took
place
process
histor
feat
develop
live
attenu
rinderpest
vaccin
play
import
role
along
epidemiolog
surveil
cull
infect
anim
live
attenu
vaccin
develop
plowright
ferri
serial
passag
virul
bovin
rinderpest
strain
kabet
primari
bovin
calf
kidney
cell
effect
vaccin
use
mani
countri
contribut
signific
reduct
incid
rinderpest
rinderpest
smallpox
viru
diseas
erad
human
effort
date
elimin
certain
anim
diseas
accomplish
vaccin
certain
countri
region
rabi
certain
european
countri
obstacl
elimin
anim
diseas
vaccin
lack
good
vaccin
difficulti
vaccin
anim
expens
largescal
vaccin
thu
develop
new
good
vaccin
still
desir
control
sever
infecti
diseas
cours
erad
rinderpest
learn
much
strategi
develop
good
vaccin
rinderpest
viru
rpv
possess
nonseg
negativestrand
rna
genom
classifi
order
mononegaviral
mononegaviral
contain
mani
pathogen
virus
thu
develop
good
vaccin
use
new
strategi
requir
despit
sever
pathogen
characterist
mononegavirus
way
thought
attract
candid
viral
vector
desir
properti
vector
first
much
known
attenu
mononegavirus
second
mononegavirus
infect
effici
via
intranas
rout
effici
induc
local
iga
system
igg
cellmedi
protect
immun
respons
third
mononegavirus
replic
cytoplasm
integr
host
genom
obviat
concern
cellular
transform
fourth
recombin
involv
mononegavirus
extrem
rare
fifth
mononegavirus
rel
simpl
genom
encod
protein
gene
mononegavirus
nonoverlap
make
easi
manipul
reason
drive
us
use
mononegavirus
viral
vector
order
mononegaviral
compris
four
famili
rhabdovirida
repres
vesicular
stomat
viru
vsv
rabi
viru
paramyxovirida
includ
sendai
viru
sev
human
parainfluenza
viru
type
measl
viru
mev
mump
virus
newcastl
diseas
viru
ndv
human
respiratori
syncyti
metapneumovirus
nipah
viru
niv
filovirida
contain
ebola
marburg
virus
bornavirida
contain
borna
diseas
viru
although
slight
differ
genom
structur
intracellular
replic
step
similar
case
paramyxovirus
virion
envelop
fusion
protein
f
attach
protein
hemagglutinin
h
hemagglutininneuraminidas
hn
glyco
g
protein
protrud
virion
surfac
matrix
protein
insid
envelop
stabil
viru
structur
regul
viral
replic
assembl
ribonucleocapsid
core
compos
genom
rna
nucleocapsid
n
protein
phosphoprotein
p
polymeras
protein
l
paramyxovirus
share
six
common
gene
transcript
start
stop
signal
gene
appear
follow
order
end
n
p
f
h
l
almost
current
use
vaccin
develop
classic
method
two
categori
licens
vaccin
use
mononegavirus
inactiv
live
vaccin
inactiv
vaccin
adjuv
nonspecif
enhanc
immun
respons
given
antigen
necessari
give
adequ
protect
immun
anim
vaccin
first
time
doubl
vaccin
requir
induc
adequ
level
immun
vaccin
rabi
viru
exampl
inactiv
vaccin
inactiv
vaccin
usual
give
rise
high
serum
antibodi
titer
howev
inactiv
vaccin
rather
ineffect
stimul
appropri
specif
cellmedi
mucos
immun
respons
thu
system
humor
immun
immunolog
memori
probabl
contribut
vaccin
immun
infecti
diseas
live
attenu
vaccin
gener
compos
virus
render
avirul
attenu
still
abl
replic
host
aim
attenu
weaken
elimin
virul
virus
without
affect
immunogen
usual
singl
vaccin
suffici
induc
high
level
immun
vaccin
rpv
canin
distemp
viru
cdv
mev
ndv
exampl
live
attenu
vaccin
immunolog
mechan
underli
protect
virus
induc
live
vaccin
probabl
involv
complex
interplay
induc
humor
cellmedi
immun
immunolog
memori
addit
classic
vaccin
type
vaccin
recombin
multival
vaccin
live
attenu
vaccin
often
consid
ideal
approach
immun
howev
alway
possibl
attenu
everi
viru
convent
method
furthermor
even
attenu
site
attenu
lesion
alway
known
revers
could
occur
overcom
disadvantag
revers
genet
use
identifi
virul
gene
virus
alter
either
mutat
delet
develop
new
attenu
vaccin
multival
vaccin
develop
use
reduc
number
vaccin
applic
simplifi
vaccin
regimen
reduc
cost
vaccin
may
reduc
risk
possibl
postvaccin
side
effect
review
focu
trial
develop
new
attenu
multival
vaccin
mononegavirus
use
recombin
techniqu
vaccinia
viru
part
play
success
erad
human
infecti
diseas
date
widespread
use
vaccinia
viru
smallpox
vaccin
especi
smallpox
erad
campaign
major
contribut
final
erad
smallpox
fenner
even
end
smallpox
erad
campaign
valu
vaccinia
viru
develop
recombin
viru
vaccin
anticip
vaccinia
viru
particularli
favor
vaccin
carrier
varieti
reason
firstli
larg
size
viral
dna
genom
allow
toler
insert
foreign
gene
report
base
pair
perku
et
al
smith
moss
secondli
vaccinia
viru
potent
induc
arm
immun
respons
shown
adequ
display
foreign
antigen
immun
respons
variou
diseas
model
pastoret
vanderplasschen
thirdli
major
advantag
use
vaccinia
viru
vaccin
vector
lyophil
vaccinia
viru
heatstabl
obviat
need
cold
chain
advantag
mani
vacciniavector
vaccin
mononegavirus
rpv
yilma
et
al
tsukiyama
et
al
barrett
et
al
cdv
wild
et
al
welter
et
al
welter
et
al
niv
wang
et
al
sev
takao
et
al
ndv
meuleman
et
al
boursnel
et
al
rabi
viru
wiktor
et
al
kieni
et
al
examin
veterinari
use
far
two
exampl
vacciniavector
vaccin
vacciniarpv
glycoprotein
recombin
vaccin
shown
first
time
suffici
attenu
authorit
trial
vacciniarabi
glycoprotein
recombin
vaccin
first
recombin
vaccinia
mump
viru
muv
use
vaccin
discuss
first
vaccinia
recombin
vaccin
rinderpest
develop
late
use
two
surfac
glycoprotein
gene
viru
f
h
protein
gene
immun
antigen
yilma
et
al
tsukiyama
et
al
barrett
et
al
base
wr
strain
viru
consid
suffici
attenu
suitabl
licens
absenc
smallpox
human
popul
addit
vaccinia
strain
produc
sever
lesion
site
inocul
anim
expert
committe
conven
oie
consid
guidelin
use
vaccin
recommend
use
safer
strain
vaccinia
shown
suffici
attenu
authorit
trial
rinderpest
recombin
base
strain
test
cattl
britain
yamanouchi
et
al
one
base
wyeth
strain
test
usa
giavedoni
et
al
subsequ
durat
immun
african
verardi
et
al
european
cattl
inui
et
al
shown
reason
longlast
certainli
suffici
control
outbreak
situat
anoth
poxviru
vector
capripox
viru
agent
sheep
goat
pox
also
use
produc
recombin
rinderpest
vaccin
use
establish
capripox
vaccin
vector
possibl
protect
cattl
two
diseas
rinderpest
lumpi
skin
diseas
latter
caus
capripox
ngichab
et
al
romero
et
al
romero
et
al
recombin
vector
consid
suitabl
use
epidem
area
rinderpest
heat
stabil
unfortun
controversi
releas
genet
manipul
organ
hamper
licens
vaccin
field
use
util
grep
rabi
infect
domest
wild
anim
seriou
problem
throughout
world
major
diseas
vector
wildlif
speci
rabi
control
focus
vaccin
andor
cull
wildlif
speci
oral
rabi
vaccin
prove
obligatori
strategi
rabi
elimin
program
domest
sever
wildlif
target
speci
tradit
live
attenu
rabi
vaccin
applic
oral
vaccin
heatinst
furthermor
live
attenu
rabi
vaccin
still
pathogen
anim
speci
case
vaccineinduc
rabi
often
report
therefor
recombin
vaccinia
viru
rel
heatstabl
viru
use
develop
safer
recombin
vaccin
rabi
viru
first
recombin
vaccinia
viru
use
vaccin
recombin
vaccinia
viru
express
rabi
viru
glycoprotein
insert
vaccinia
viru
thymidin
kinas
gene
wiktor
et
al
kieni
et
al
vaccin
use
oral
bait
distribut
hand
aerial
distribut
low
fli
aircraft
target
area
vaccin
wide
use
oral
vaccin
raccoon
gray
fox
coyot
north
america
raccoon
canada
red
fox
sever
western
european
countri
cliquet
aubert
rupprecht
et
al
rupprecht
et
al
blancou
et
al
viru
also
use
immun
import
reservoir
rabi
vampir
bat
aguilarsetien
et
al
although
use
certain
campaign
great
success
potenti
safeti
issu
relat
use
potent
vaccinia
viru
hamper
expans
use
new
target
speci
new
area
neg
strand
rna
virus
includ
mononegavirus
imposs
gener
recombin
viru
clone
cdna
rna
genom
long
time
schnell
mebats
conzelmann
develop
revers
genet
system
rabi
viru
allow
recoveri
infecti
viru
entir
clone
cdna
schnell
et
al
follow
quickli
develop
revers
genet
system
numer
mononegavirus
revers
genet
use
molecular
virolog
gener
infecti
virus
possess
genom
deriv
clone
cdna
modifi
order
studi
consequ
effect
phenotyp
one
characterist
mononegavirus
genom
locat
exclus
cytoplasm
infect
cell
go
dna
phase
thu
concern
unwant
integr
foreign
sequenc
chromosom
dna
therefor
new
class
cytoplasm
rna
vector
expect
safer
effici
viral
vector
exist
vector
applic
human
therapi
variou
field
includ
gene
therapi
vaccin
mononegavirus
requir
attenu
use
potenti
vector
high
cytopath
effect
revers
genet
power
tool
introduc
combin
attenu
mutat
delet
rna
genom
finetun
level
attenu
produc
vaccin
suffici
infecti
immunogen
yet
attenu
genet
stabl
end
attenu
amino
acid
point
mutat
identifi
introduc
desir
combin
revers
genet
inactiv
immunemodul
viral
protein
accessori
protein
revers
genet
provid
optim
method
increas
efficaci
vaccin
reduc
pathogen
vaccin
vector
improv
delet
enveloperel
gene
genom
exampl
delet
enveloperel
gene
f
hn
sev
genom
effect
reduc
cytopath
reaction
yoshizaki
et
al
modif
revers
genet
expect
improv
safeti
broaden
rang
clinic
applic
new
class
cytoplasm
rna
vector
follow
discuss
use
mononegavirus
particular
member
rhabdovirida
paramyxovirida
live
vaccin
vector
case
vsv
sever
uniqu
strategi
attenu
attempt
truncat
cytoplasm
tail
ct
region
g
protein
use
attenu
vitro
growth
vivo
virul
recombin
vsv
vector
robert
et
al
schnell
et
al
virus
shorten
ct
slower
growth
rate
reach
lower
peak
titer
vitro
less
pathogen
mice
unalt
virus
robert
et
al
thought
shorter
ct
reduc
rate
particl
format
peak
viru
titer
produc
vitro
possibl
due
impair
ct
interact
viral
core
protein
robert
et
al
schnell
et
al
dubovi
wagner
jayakar
et
al
next
abil
attenu
vitro
growth
virul
recombin
vsv
move
n
gene
first
posit
genom
downstream
locat
clearli
demonstr
flanagan
et
al
flanagan
et
al
wertz
et
al
stepwis
transloc
n
gene
away
transcript
promot
lead
increment
reduct
n
protein
express
consequ
limit
n
protein
reduc
level
nucleocapsid
avail
transcript
replic
subsequ
incorpor
viru
progeni
mutant
give
rise
viru
stabl
attenu
phenotyp
replac
delet
sequenc
encod
part
protein
improb
third
attenu
strategi
reli
nucleotid
substitut
within
gene
ablat
express
two
infram
overlap
polypeptid
initi
downstream
protein
translat
start
codon
jayakar
whitt
virus
express
polypeptid
demonstr
reduc
cytopatholog
varieti
cell
line
highli
attenu
mice
consequ
mutant
express
polypeptid
call
noncytopath
mutant
result
combin
mutant
growth
attenu
vitro
vector
contain
either
singl
form
mutat
clark
et
al
result
show
synergist
rather
cumul
increas
attenu
demonstr
new
approach
attenu
vsv
possibl
virus
ndv
caus
seriou
respiratori
diseas
poultri
engin
recombin
ndv
express
chloramphenicol
acetyltransferas
cat
gener
revers
genet
krishnamurthi
et
al
cat
gene
recombin
ndv
maintain
stabli
least
eight
passag
without
detect
loss
gene
howev
viru
show
reduc
plaqu
size
slower
replic
kinet
increas
mean
death
time
egg
lower
intracerebr
pathogen
index
dayold
chick
implic
attenu
recombin
viru
thu
introduct
addit
gene
ndv
genom
repres
altern
method
achiev
viral
attenu
recent
uniqu
altern
method
viral
attenu
refer
death
thousand
cut
strategi
report
coleman
et
al
result
redund
genet
code
speciesspecif
codon
pair
bia
mean
synonym
codon
pair
use
less
frequent
statist
expect
recombin
poliovirus
underrepres
codon
pair
show
decreas
rate
viral
protein
translat
attenu
mice
furthermor
recombin
poliovirus
use
immun
mice
provid
protect
immun
challeng
method
three
key
advantag
use
vaccin
previou
method
produc
viru
encod
precis
amino
acid
sequenc
wildtyp
viru
therefor
induc
immun
respons
ii
attenu
subject
revers
simpli
sheer
number
mutat
iii
use
combin
attenu
approach
describ
thu
virus
attenu
method
candid
novel
attenu
viru
vaccin
futur
v
c
protein
produc
p
gene
widespread
among
member
subfamili
paramyxovirina
famili
paramyxovirida
ubiquit
six
major
structur
protein
therefor
regard
nonessenti
accessori
gene
product
open
read
frame
orf
shift
orf
p
protein
give
rise
c
protein
divers
accomplish
use
translat
initi
codon
start
differ
point
frame
c
protein
therefor
access
ribosom
choic
v
protein
hand
produc
g
residu
insert
edit
site
within
p
orf
viral
rna
polymeras
occur
constant
rate
v
protein
therefor
consist
pv
common
region
v
uniqu
region
virus
subject
variou
antivir
host
respons
upon
infect
among
respons
interferon
ifn
respons
play
import
role
earli
innat
immun
modul
subsequ
acquir
immun
accessori
protein
variou
paramyxovirus
shown
ifnantagonist
activ
play
import
role
pathogen
vivo
exampl
c
protein
respiroviru
v
protein
paramyxovirus
shown
prevent
ifn
respons
inhibit
ifn
signal
gotoh
et
al
addit
v
protein
paramyxovirus
abl
antagon
nfkb
arm
dsrna
signal
pool
et
al
child
et
al
identifi
interact
partner
v
protein
child
et
al
andrejeva
et
al
date
variou
recombin
virus
lack
accessori
protein
establish
attenu
examin
vivo
silenc
accessori
protein
practic
recombin
virus
lack
protein
frequent
grow
high
titer
cultur
cell
featur
necessari
effici
prepar
vaccin
great
relev
attenu
vaccin
develop
ndv
edit
p
gene
mrna
insert
nontempl
g
residu
conserv
edit
site
produc
v
protein
one
nucleotid
substitut
edit
site
result
reduc
edit
frequenc
result
v
protein
express
level
mebats
et
al
recombin
ndv
lowlevel
v
protein
express
shown
immunogen
lack
pathogen
chicken
embryo
unlik
current
avail
ndv
vaccin
strain
demonstr
potenti
use
recombin
ndv
safe
embryo
vaccin
case
sev
cdefici
viru
grow
mice
produc
lung
lesion
strike
contrast
wildtyp
sev
grew
vigor
kill
mice
furthermor
demonstr
virul
c
protein
vivo
parallel
anti
capac
vitro
hand
vdefici
viru
prolifer
lung
normal
mice
effici
parent
wildtyp
sev
day
post
infect
howev
rapidli
clear
never
lethal
kato
et
al
v
protein
contribut
prolong
viru
growth
lung
via
unknown
innateimmun
mechan
follow
activ
similarli
vdefici
possess
c
protein
accessori
protein
schaapnutt
et
al
cdefici
possess
v
protein
accessori
protein
bartlett
et
al
show
signific
attenu
vivo
undetect
level
african
green
monkey
respiratori
tract
howev
report
impli
accessori
protein
indispens
paramyxovirus
vivo
case
mev
vand
cdefici
virus
develop
attenu
clinic
symptom
shortliv
replic
rhesu
monkey
degre
attenu
mild
compar
virus
describ
interestingli
cdv
v
protein
essenti
rapid
viral
multipl
cell
cdefect
cdv
remain
fulli
virul
immunosuppress
hand
cdefect
significantli
attenu
vivo
vknockout
affect
replic
vivo
durbin
et
al
divers
activ
accessori
protein
vivo
confirm
studi
use
rpv
niv
lapin
strain
viru
rpvl
deriv
vaccin
viru
numer
passag
rabbit
avirul
cattl
highli
virul
rabbit
caus
clinic
sign
ident
rinderpest
cattl
contrast
tissu
cultur
attenu
rbok
strain
vaccin
strain
caus
diseas
rabbit
use
strain
construct
chimer
viru
l
rbok
gene
replac
result
recombin
virus
harbor
p
gene
l
strain
show
clinic
virolog
histopatholog
sign
rabbit
indic
rpv
p
gene
consid
key
determin
pathogen
yoneda
et
al
yoneda
et
al
unexpectedli
howev
vdefici
cdefici
rpvl
show
sever
clinic
symptom
rabbit
similar
effect
parent
strain
unpublish
data
studi
demonstr
accessori
protein
rpv
exert
littl
effect
virul
viro
first
develop
niv
revers
genet
system
yoneda
et
al
niv
first
discov
malaysia
outbreak
infect
pig
human
incur
high
fatal
rate
human
niv
broad
host
rang
natur
host
identifi
fruit
bat
human
infect
induc
high
mortal
rate
recent
outbreak
bangladesh
kai
yoneda
broad
host
rang
high
mortal
rate
associ
infect
niv
classifi
biosafeti
level
agent
thu
attenu
step
import
handl
develop
vaccin
niv
futur
urgent
issu
prevent
outbreak
case
niv
p
gene
express
w
protein
gener
two
g
residu
insert
edit
site
addit
p
v
c
report
four
p
gene
product
ifn
antagonist
activ
vitro
addit
v
w
inhibit
ifn
product
gener
recombin
niv
lack
v
c
w
protein
respect
analyz
function
protein
infect
cell
implic
vivo
pathogen
yoneda
et
al
although
also
confirm
ifn
antagonist
activ
accessori
protein
protein
express
cell
recombin
lack
accessori
protein
suppress
ifn
respons
well
parent
niv
fig
indic
lack
singl
accessori
protein
significantli
affect
inhibit
ifn
signal
infect
cell
recombin
niv
lack
accessori
protein
possess
unalt
p
protein
thu
p
protein
might
enough
inhibit
ifn
signal
expect
wdefici
viru
show
appar
differ
virul
compar
wildtyp
experiment
infect
golden
hamster
fig
howev
interestingli
vor
cdefici
niv
show
signific
reduct
virul
fig
result
suggest
v
c
protein
w
protein
play
key
role
niv
pathogen
role
independ
ifnantagonist
activ
studi
indic
recombin
niv
lack
c
v
could
good
candid
attenu
vaccin
niv
attempt
gener
safer
vector
use
mononegaviru
replicationdefect
viru
also
studi
sev
li
et
al
genom
cdna
construct
replac
f
gene
egfp
report
gene
addit
provid
f
protein
fexpress
packag
cell
line
creloxpinduc
express
system
construct
recombin
sev
encod
f
protein
instead
incorpor
express
tran
thu
defect
vector
amplifi
specif
fexpress
packag
cell
line
spread
fnonexpress
cell
furthermor
insert
egfp
report
gene
vigor
express
sev
vector
cell
variou
origin
cultur
viral
vector
induct
antibodi
tcellmedi
immun
respons
mice
yoshizaki
et
al
therefor
fdefici
sev
vector
promis
vaccin
tool
induc
virusspecif
cellular
immun
respons
current
system
thought
serv
deliveri
vector
wide
rang
divid
nondivid
mammalian
cell
tissu
replicationdefect
viru
also
use
handl
deadli
diseas
ebola
virus
ebov
caus
hemorrhag
fever
human
nonhuman
primat
case
fatal
rate
outbreak
categor
thu
biolog
contain
ebov
resembl
wildtyp
viru
handl
outsid
contain
clearli
need
end
ebov
lack
essenti
gene
gener
maintain
cell
line
express
result
virus
resembl
wildtyp
viru
life
cycl
morpholog
growth
properti
halfmann
et
al
next
protect
efficaci
ebov
two
anim
model
mice
guinea
pig
assess
mice
immun
twice
defect
viru
protect
lethal
infect
mouseadapt
ebov
viru
titer
serum
vaccin
mice
significantli
lower
nonvaccin
mice
protect
mice
immun
defect
ebov
associ
high
antibodi
respons
ebov
glycoprotein
gener
ebov
npspecif
tcell
respons
guinea
pig
immun
twice
defect
viru
also
protect
lethal
infect
guinea
pigadapt
ebov
halfmann
et
al
studi
demonstr
potenti
ebov
new
vaccin
platform
global
vaccin
programm
could
difficult
distinguish
natur
infect
anim
vaccin
anim
detect
serolog
respons
intrins
viral
antigen
fact
rinderpest
erad
programm
lifelong
immun
induc
vaccin
confus
serosurveil
differenti
noninfect
vaccin
anim
expos
rpv
case
part
final
strategi
erad
rinderpest
emerg
vaccin
plan
prevent
spread
viru
event
isol
outbreak
diseas
endem
region
solv
problem
type
marker
vaccin
develop
use
revers
genet
techniqu
exampl
recombin
rpv
express
ha
gfp
membraneanchor
form
gfp
establish
walsh
et
al
b
vaccin
highli
effect
protect
anim
virul
rinderpest
challeng
enabl
identif
vaccin
anim
serolog
neg
marker
vaccin
replac
n
protein
gene
rpv
equival
gene
pest
de
petit
rumin
viru
pprv
highli
contagi
diseas
small
rumin
classifi
morbilliviru
genu
along
rpv
consid
use
even
erad
programm
vaccin
produc
strong
n
protein
specif
antibodi
respons
found
natur
infect
tradit
vaccin
parida
et
al
contrari
one
recombin
pprv
vaccin
develop
use
rinderpest
vaccin
viru
genom
backbon
f
h
gene
rpv
replac
pprv
mahapatra
et
al
result
chimer
viru
prove
safe
effect
vaccin
could
protect
goat
virul
challeng
pprv
chimer
ppr
marker
vaccin
use
endem
countri
without
compromis
global
rinderpest
serosurveil
effort
sinc
antibodi
test
base
either
n
h
protein
quit
distinguish
serolog
rinderpest
ppr
virus
logic
extens
work
obtain
improv
vaccin
individu
virus
explor
potenti
mononegavirus
multival
vaccin
vector
begun
common
goal
gener
protect
immun
respons
pathogen
mononegavirus
ideal
featur
live
vaccin
caus
homolog
recombin
infect
cell
induc
humor
cellular
immun
addit
mononegavirus
amen
genet
manipul
revers
genet
system
transcript
unit
code
foreign
gene
insert
viral
gene
start
stop
signal
foreign
gene
express
along
viral
gene
viral
replic
phenomenon
transcript
polar
govern
level
express
correspond
protein
present
immunogen
context
viral
infect
may
act
adjuv
exampl
vsv
evalu
vaccin
vector
number
preval
human
virus
includ
hiv
clark
et
al
sarscov
kapadia
et
al
herp
simplex
viru
type
natuk
et
al
papillomaviru
robert
et
al
hepat
c
viru
buonocor
et
al
furthermor
sever
rvsv
vector
alreadi
gener
express
variou
cytokin
vector
weak
adjuv
effect
posit
result
rvsv
vector
express
kla
et
al
kla
et
al
gmcsf
ramsburg
et
al
report
proinflammatori
cytokin
express
antigenpres
cell
heterodim
drive
develop
respons
gmcsf
recruit
activ
antigenpres
cell
includ
macrophag
dendrit
cell
paramyxovirus
current
develop
multival
vaccin
vector
human
use
exampl
recombin
mev
express
hepat
b
viru
singh
et
al
del
vall
et
al
hiv
tangi
naim
brandler
et
al
zuniga
et
al
west
nile
dengu
viru
brandler
et
al
despr
et
al
brandler
tangi
sarscov
linig
et
al
establish
also
develop
recombin
mev
vaccin
hepat
c
viru
satoh
et
al
kasama
et
al
niv
unpublish
data
case
sev
uniqu
attempt
use
sev
express
amyloid
peptid
therapi
alzheim
diseas
perform
tabira
hara
hand
develop
multival
vaccin
vector
veterinari
use
advanc
date
follow
section
present
recent
attempt
develop
canin
vaccin
cdv
pathogen
canin
distemp
one
lethal
infecti
diseas
dog
canida
takayama
et
al
hirama
et
al
ohashi
et
al
present
fever
pneumonia
bronchiti
leukopenia
sever
diarrhea
sometim
enceph
cdv
caus
agent
member
famili
paramyxovirida
genu
morbilliviru
includ
mev
rpv
pprv
recent
dramat
epidem
cdv
unexpect
host
speci
lion
roelkepark
et
al
larg
felid
morel
seal
kennedi
et
al
mamaev
et
al
osterhau
et
al
rais
addit
concern
appar
expand
host
rang
cdv
potenti
threat
cdv
wild
carnivor
popul
mani
region
world
cdv
occur
gener
introduct
live
attenu
cdv
vaccin
extens
use
drastic
reduc
incid
canin
distemp
dog
abil
elicit
lifelong
immun
howev
canin
distemp
outbreak
previous
immun
dog
becom
infect
recent
observ
iwatsuki
et
al
blixenkronemol
et
al
rais
question
whether
vaccin
current
use
effici
protect
presentday
circul
wildtyp
thu
avail
extrem
safe
live
attenu
cdv
vaccin
recent
preval
strain
ideal
base
develop
multival
vaccin
previou
studi
demonstr
recent
isol
cdvyanaka
strain
iwatsuki
et
al
avirul
dog
dog
vaccin
yanaka
strain
complet
protect
virul
cdv
challeng
unpublish
data
may
expect
recombin
cdv
insert
gene
encod
neutral
epitop
pathogen
induc
longterm
immun
cdv
pathogen
leishmaniasi
distribut
part
countri
million
peopl
tropic
subtrop
region
leishmaniasi
caus
infect
parasit
protozoa
leishmania
parasit
natur
transmit
bloodsuck
sand
fli
among
reservoir
anim
includ
rodent
dog
human
accident
host
transmit
anim
epidemiolog
report
brazil
elimin
canin
leishmaniasi
correl
decreas
preval
diseas
human
dietz
et
al
howev
effect
vaccin
human
even
dog
vanloubbeeck
jone
develop
vaccin
target
leishmania
construct
recombin
cdvyanaka
protect
antigen
leishmania
major
strain
leishmania
evalu
efficaci
recombin
cdv
polyval
vaccin
cdv
leishmania
infect
l
major
inocul
dog
intraderm
usual
prolifer
site
inocul
form
nodul
skin
lesion
week
leishmania
challeng
nodul
grown
larger
unvaccin
dog
top
nodul
ulcer
fig
contrast
size
nodul
appar
much
smaller
dog
vaccin
cdv
express
leishmania
antigen
control
result
show
recombin
cdv
vaccin
induc
signific
protect
immun
effect
suppress
delay
prolifer
leishmania
earli
stage
studi
show
power
tool
prevent
leishmaniasi
epidem
disrupt
infect
root
dog
recombin
cdv
base
yanaka
strain
consid
superior
convent
vaccin
strain
polyval
vaccin
vector
use
system
also
develop
dival
vaccin
cdv
dog
virus
sinc
domest
puppi
vaccin
live
attenu
cdv
vaccin
dival
vaccin
cdv
dog
virus
could
good
futur
candid
ideal
vaccin
dog
vaccin
import
strategi
control
viru
diseas
vaccin
develop
classic
method
effect
mani
virus
fact
classic
vaccin
play
key
role
erad
two
import
virus
smallpox
viru
rpv
howev
classic
vaccin
still
disadvantag
thu
develop
ideal
vaccin
use
new
method
still
requir
sinc
revers
genet
mononegavirus
establish
techniqu
appli
develop
vaccin
mani
particular
revers
genet
technolog
allow
us
design
improv
vaccin
mononegavirus
also
multival
vaccin
induc
humor
cellular
immun
respons
pathogen
new
vaccin
develop
efficaci
safeti
novel
vaccin
first
evalu
use
control
anim
viru
infecti
diseas
studi
vaccin
develop
anim
mononegaviru
diseas
give
us
valuabl
knowledg
appli
scienc
also
basic
issu
molecular
determin
viru
virul
final
contribut
health
develop
new
vaccin
use
revers
genet
techniqu
could
promis
way
ideal
vaccin
mononegavirus
